American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes (2004). Journal of Clinical Psychiatry 65, 267–272.
Brown, S (1997). Excess mortality of schizophrenia. A meta-analysis. British Journal of Psychiatry 171, 502–508.
Cheng, F, Jones, PB (2010). Second-generation atypical versus first-generation conventional antipsychotic drug treatment in schizophrenia: another triumph of hope over experience? In Therapeutic Strategies in Schizophrenia (ed. Mortimer, AM and McKenna, PJ), pp. 193–206. Clinical Publishing: Oxford, UK.
Chen, CK, Chen, YC, Huang, YS (2009). Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up. Psychiatry and Clinical Neurosciences 63, 17–22.
Citrome, L (2011a). Iloperidone: a clinical overview. Journal of Clinical Psychiatry 72 (Suppl. 1), 19–23.
Citrome, L (2011b). Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. International Journal of Clinical Practice 65, 189–210.
Davis, JM, Chen, N, Glick, ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60, 553–564.
Ernst, E, Canter, PH (2005). Limitations of “pragmatic” trials. Postgraduate Medical Journal 81, 203.
Geddes, J, Freemantle, N, Harrison, P, Bebbington, P (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 321, 1371–1376.
Healy, D (2002). The Creation of Psychopharmacology. Harvard University Press: Cambridge, MA.
Hotopf, M, Churchill, R, Lewis, G (1999). Pragmatic randomised controlled trials in psychiatry. British Journal of Psychiatry 175, 217–223.
Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, Murray, RM, Markwick, A, Lewis, SW (2006). Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63, 1079–1087.
Kahn, RS, Fleischhacker, WW, Boter, H, Davidson, M, Vergouwe, Y, Keet, IP, Gheorghe, MD, Rybakowski, JK, Galderisi, S, Libiger, J, Hummer, M, Dollfus, S, Lopez-Ibor, JJ, Hranov, LG, Gaebel, W, Peuskens, J, Lindefors, N, Riecher-Rossler, A, Grobbee, DE (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085–1097.
Kane, J, Honigfeld, G, Singer, J, Meltzer, H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789–796.
Klemp, M, Tvete, IF, Skomedal, T, Gaasemyr, J, Natvig, B, Aursnes, I (2011). A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. Journal of Clinical Psychopharmacology 31, 698–704.
Leucht, S, Pitschel-Walz, G, Abraham, D, Kissling, W (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35, 51–68.
Leucht, S, Wahlbeck, K, Hamann, J, Kissling, W (2003). New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361, 1581–1589.
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31–41.
Lewis, SW, Barnes, TR, Davies, L, Murray, RM, Dunn, G, Hayhurst, KP, Markwick, A, Lloyd, H, Jones, PB (2006). Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 32, 715–723.
Lieberman, J, Jody, D, Geisler, S, Alvir, J, Loebel, A, Szymanski, S, Woerner, M, Borenstein, M (1993). Time course and biologic correlates of treatment response in first-episode schizophrenia. Archives of General Psychiatry 50, 369–376.
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, Keefe, RS, Davis, SM, Davis, CE, Lebowitz, BD, Severe, J, Hsiao, JK (2005). Clinical Antipsychotic Trials of Intervention Effectivness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209–1223.
Malla, AK, Norman, RM, Scholten, DJ, Zirul, S, Kotteda, V (2001). A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. Journal of Clinical Psychiatry 62, 179–184.
Marder, S, Jones, PB (2008). Pharmacological treatments for schizophrenia. In Cambridge Textbook of Effective Treatments in Schizophrenia (ed. Tyrer, P and Silk, R), Cambridge University Press: Cambridge.
Marder, SR, Essock, SM, Miller, AL, Buchanan, RW, Casey, DE, Davis, JM, Kane, JM, Lieberman, JA, Schooler, NR, Covell, N, Stroup, S, Weissman, EM, Wirshing, DA, Hall, CS, Pogach, L, Pi-Sunyer, X, Bigger, JT Jr., Friedman, A, Kleinberg, D, Yevich, SJ, Davis, B, Shon, S (2004). Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161, 1334–1349.
Marson, A, Kadir, Z, Chadwick, D (1997). Large pragmatic randomised studies of new antiepileptic drugs are needed. British Medical Journal 314, 1764.
McEvoy, JP, Lieberman, JA, Stroup, TS, Davis, SM, Meltzer, HY, Rosenheck, RA, Swartz, MS, Perkins, DO, Keefe, RS, Davis, CE, Severe, J, Hsiao, JK (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163, 600–610.
McEvoy, JP, Lieberman, JA, Perkins, DO, Hamer, RM, Gu, H, Lazarus, A, Sweitzer, D, Olexy, C, Weiden, P, Strakowski, SD (2007). Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. American Journal of Psychiatry 164, 1050–1060.
Patil, ST, Zhang, L, Martenyi, F, Lowe, SL, Jackson, KA, Andreev, BV, Avedisova, AS, Bardenstein, LM, Gurovich, IY, Morozova, MA, Mosolov, SN, Neznanov, NG, Reznik, AM, Smulevich, AB, Tochilov, VA, Johnson, BG, Monn, JA, Schoepp, DD (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Medicine 13, 1102–1107.
Peluso, MJ, Lewis, SW, Barnes, TR, Jones, PB (2012). Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. British Journal of Psychiatry 200, 387–392.
Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. American Academy of Child and Adolescent Psychiatry (2001). Journal of the American Academy of Child and Adolescent Psychiatry 40, 4S–23S.
Robinson, DG, Woerner, MG, Alvir, JM, Geisler, S, Koreen, A, Sheitman, B, Chakos, M, Mayerhoff, D, Bilder, R, Goldman, R, Lieberman, JA (1999). Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 156, 544–549.
Rosenheck, RA (2008). Pharmacotherapy of first-episode schizophrenia. Lancet 371, 1048–1049.
Schoemaker, J, Naber, D, Vrijland, P, Panagides, J, Emsley, R (2010). Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 43, 138–146.
Schooler, N, Rabinowitz, J, Davidson, M, Emsley, R, Harvey, PD, Kopala, L, McGorry, PD, Van Hove, I, Eerdekens, M, Swyzen, W, De Smedt, G (2005). Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. American Journal of Psychiatry 162, 947–953.
Sikich, L, Frazier, JA, McClellan, J, Findling, RL, Vitiello, B, Ritz, L, Ambler, D, Puglia, M, Maloney, AE, Michael, E, De Jong, S, Slifka, K, Noyes, N, Hlastala, S, Pierson, L, McNamara, NK, Delporto-Bedoya, D, Anderson, R, Hamer, RM, Lieberman, JA (2008). Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. American Journal of Psychiatry 165, 1420–1431.
Stoner, SC, Pace, HA (2012). Asenapine: a clinical review of a second-generation antipsychotic. Clinical Therapeutics 34, 1023–1040.
Tiihonen, J, Lonnqvist, J, Wahlbeck, K, Klaukka, T, Niskanen, L, Tanskanen, A, Haukka, J (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374, 620–627.
Tunis, SR, Stryer, DB, Clancy, CM (2003). Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. Journal of the American Medical Association 290, 1624–1632.
Turner, T (2007). Chlorpromazine: unlocking psychosis. British Medical Journal 334 (Suppl. 1), s7.
Zarin, DA, Young, JL, West, JC (2005). Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. Social Psychiatry and Psychiatric Epidemiology 40, 27–35.
Zhang-Wong, J, Zipursky, RB, Beiser, M, Bean, G (1999). Optimal haloperidol dosage in first-episode psychosis. Canadian Journal of Psychiatry 44, 164–167.
Zwarenstein, M, Treweek, S, Gagnier, JJ, Altman, DG, Tunis, S, Haynes, B, Oxman, AD, Moher, D (2008). Improving the reporting of pragmatic trials: an extension of the CONSORT statement. British Medical Journal 337, a2390.